| Not Yet Recruiting | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration NCT07421414 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration NCT07421401 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration NCT07421388 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration NCT07421375 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription NCT07424118 | Evelyn Vanina Re | N/A |
| Not Yet Recruiting | A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension NCT07373613 | Boryung Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Mat Pilates With Paced Breathing Versus Diaphragmatic Breathing in Stage II Hypertension NCT07433790 | University of Lahore | N/A |
| Recruiting | Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers NCT07282145 | Bichedam Co., Ltd. | Phase 1 |
| Recruiting | Childhood-Onset Essential Hypertension Natural History Study NCT06778239 | National Human Genome Research Institute (NHGRI) | — |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of NCT06889012 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension NCT07051811 | Lepu Medical Technology (Beijing) Co., Ltd. | N/A |
| Completed | A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension NCT06671392 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Enrolling By Invitation | A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adoles NCT06863987 | Shandong New Time Pharmaceutical Co., LTD | Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration o NCT06744439 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration o NCT06744062 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration o NCT06744426 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration o NCT06744127 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension NCT06682000 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Not Yet Recruiting | QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension NCT06716970 | Wuhan Createrna Science and Technology Co., Ltd | Phase 3 |
| Unknown | Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension NCT06091176 | Newel Health SRL | N/A |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration NCT06636877 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A NCT06643819 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration b NCT06889064 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity NCT06418074 | Gødstrup Hospital | N/A |
| Completed | Effects of Antihypertensive Drug Treatment on Brain Blood Flow, Cognition, and Regulation of Nervous System in NCT06287580 | University of Texas Southwestern Medical Center | EARLY_Phase 1 |
| Recruiting | Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM） NCT06877234 | Shenzhen Pulsecare Medical Technology Co., Ltd. | N/A |
| Recruiting | Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in NCT05880056 | Genuine Research Center, Egypt | Phase 4 |
| Not Yet Recruiting | Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy NCT06501651 | Sichuan Academy of Medical Sciences | Phase 4 |
| Recruiting | Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study NCT06568640 | Second Affiliated Hospital of Nanchang University | N/A |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B NCT06441630 | Addpharma Inc. | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy NCT06220773 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C NCT06165250 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial NCT06141200 | Natural Wellness Egypt | Phase 3 |
| Unknown | Feasibility Study Evaluating the Safety and Efficacy of the Renal Stimulation by Direct Wire Pacing, During Re NCT06235554 | Ceric Sàrl | N/A |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration NCT06226727 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Unknown | Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment NCT05947448 | Hasten Biopharmaceutical Co., Ltd. | — |
| Completed | Sleep Hygiene Education and Blood Pressure Control in Essential Hypertension in Primary Care NCT07257237 | Ozturk Gurer Tutu, MD | N/A |
| Completed | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administrati NCT06184269 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Unknown | Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension NCT03945305 | Yi Yang | N/A |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension NCT06041529 | Yuhan Corporation | Phase 4 |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Mo NCT06121518 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertensi NCT05930028 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Feasibility and Effectiveness of a Ring-type Blood Pressure Measurement Device NCT06084065 | Seoul National University Hospital | N/A |
| Completed | Effect of DNS Exercises Training on Hypertension NCT05900713 | Cairo University | N/A |
| Completed | Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy NCT05931224 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH) NCT05910242 | Yi Yang | N/A |
| Completed | A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers NCT05993806 | Celltrion | Phase 1 |
| Unknown | A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive P NCT05843162 | Chong Kun Dang Pharmaceutical | Phase 4 |
| Recruiting | Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension NCT05845905 | Yi Yang | N/A |
| Unknown | S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement NCT06130124 | Hanlim Pharm. Co., Ltd. | — |
| Active Not Recruiting | Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension NCT06604897 | Novartis | — |
| Unknown | Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type I NCT05573477 | Autotelicbio | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy NCT05878561 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Technological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper NCT05843682 | University of Sao Paulo General Hospital | N/A |
| Unknown | Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy NCT05526703 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Unknown | Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequa NCT05503953 | Ahn-Gook Pharmaceuticals Co.,Ltd | Phase 3 |
| Completed | The Plasma Metabolomics Profiling of Primary Aldosteronism NCT06500000 | Third Military Medical University | — |
| Completed | Effect of Motivational Interviews on Cardiovascular Disease Risks and Healthy Lifestyle Behavior Changes NCT05390931 | Eskisehir Osmangazi University | N/A |
| Completed | Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypert NCT05475665 | Handok Inc. | Phase 3 |
| Completed | Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Es NCT05385770 | Celltrion | Phase 3 |
| Completed | Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertensio NCT05476354 | Handok Inc. | Phase 3 |
| Recruiting | Efficacy and Safety of AJU-C52 in Essential Hypertension Patients NCT06416865 | AJU Pharm Co., Ltd. | Phase 3 |
| Completed | A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension NCT07116863 | Kyungdong Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension NCT06282549 | Yuhan Corporation | — |
| Unknown | Evaluation of Black Chokeberry Bio Juice on Blood Pressure Levels and Endothelial Damage NCT05912322 | University of Medicine and Pharmacy "Victor Babes" Timisoara | N/A |
| Unknown | Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI NCT05103813 | Shenzhen People's Hospital | EARLY_Phase 1 |
| Completed | Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension NCT06212648 | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 |
| Recruiting | A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China NCT05638269 | Zhujiang Hospital | — |
| Completed | To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontroll NCT06500689 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 |
| Completed | Physical Activity, Air Pollution, and High Blood Pressure NCT05092672 | University of British Columbia | N/A |
| Unknown | Juvenile Essential Arterial Hypertension and Vascular Function NCT05109013 | Josip Juraj Strossmayer University of Osijek | — |
| Completed | Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension NCT05359068 | Shanghai Pharmaceuticals Holding Co., Ltd | Phase 3 |
| Completed | To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine NCT06465264 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 3 |
| Unknown | Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn NCT06090617 | University Hospital Padova | — |
| Unknown | Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension NCT04554303 | Ahn-Gook Pharmaceuticals Co.,Ltd | — |
| Completed | The Effect of the Use of BATHE Interview Technique on Treatment Compliance in Hypertension Patients in Primary NCT05476120 | Dokuz Eylul University | N/A |
| Completed | Repurposing Colchicine to Improve Vascular Function in Hypertension NCT04303689 | University of Copenhagen | N/A |
| Unknown | s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension NCT05033535 | Shenzhen People's Hospital | Phase 2 |
| Completed | Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients W NCT04488978 | Handok Inc. | Phase 2 |
| Unknown | Effect of Atorvastatin on Carotid Intima Media Thickness NCT04306627 | Yerevan State Medical University | Phase 4 |
| Completed | Personal Activity Intelligence in the Treatment of High Blood Pressure NCT04151537 | Norwegian University of Science and Technology | N/A |
| Completed | A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea NCT04470830 | Celltrion Pharm, Inc. | — |
| Completed | Heat Therapy in Older Hypertensive Women NCT03857490 | University of Texas Southwestern Medical Center | N/A |
| Completed | BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine NCT03991442 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Sympathetic Mapping/ Ablation of Renal Nerves Trial (SMART) HTN-OFF MED Study NCT03885843 | The Second Affiliated Hospital of Chongqing Medical University | N/A |
| Completed | LCZ696 in Advanced LV Hypertrophy and HFpEF NCT03928158 | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Phase 2 |
| Completed | Effect of Breathing and Muscle Relaxation Technique in Individual With Essential Hypertension NCT05684666 | King Saud University | N/A |
| Unknown | Effects of Aromatherapy in Hypertensive Individuals NCT04460300 | Abant Izzet Baysal University | N/A |
| Unknown | Clinical Trial on Remote Ischemic Conditioning and Hypertension（HOPE） NCT03566654 | Ji Xunming,MD,PhD | Phase 2 |
| Completed | A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea NCT04470817 | Celltrion Pharm, Inc. | — |
| Completed | Vedic Medical Astrology in Essential Hypertension NCT03803306 | NMP Medical Research Institute | N/A |
| Completed | FimasaRtan-basEd BP Targets After Drug SwitcHing NCT03649646 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginin NCT05288400 | Servier | Phase 3 |
| Completed | Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial NCT03371797 | PharmEvo Pvt Ltd | — |
| Unknown | Study MIPAE - Melatonin and Essential Arterial Hypertension NCT05257291 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Phase 2 |
| Completed | Effect of Aerobic Exercise in Patients With Essential Hypertension NCT05987436 | TC Erciyes University | — |
| Completed | An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hype NCT03514641 | Theracos | Phase 2 / Phase 3 |
| Completed | Evaluation of a Transmedial Psychoeducational Program to Improve Pharmacological Adherence NCT03924115 | Universidad de Concepcion | N/A |
| Completed | Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia NCT03156842 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT) NCT03708601 | Beijing Institute of Heart, Lung and Blood Vessel Diseases | — |
| Completed | Study of CS-3150 in Patients With Essential Hypertension NCT02890173 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Completed | Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension NCT02848170 | Daiichi Sankyo Co., Ltd. | N/A |
| Completed | Safety Study of RMJH-111b to Treat Essential Hypertension NCT02822222 | RMJ Holdings, LLC | Phase 1 / Phase 2 |
| Completed | Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patie NCT02722265 | Daiichi Sankyo Co., Ltd. | Phase 3 |
| Completed | Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension NCT02603809 | Idorsia Pharmaceuticals Ltd. | Phase 2 |
| Unknown | S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension NCT03226340 | Seoul National University Bundang Hospital | Phase 4 |
| Unknown | Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension NCT03063697 | Chong Kun Dang Pharmaceutical | — |
| Completed | Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension NCT02480764 | Takeda | Phase 3 |
| Completed | Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate NCT02612298 | Sumitomo Pharma (Suzhou) Co., Ltd. | Phase 4 |
| Completed | Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia NCT02517866 | Takeda | Phase 4 |
| Completed | Observational Study of Efficacy and Safety of Nebivolol in Korean Patients With Essential Hypertension NCT03847350 | A.Menarini Asia-Pacific Holdings Pte Ltd | — |
| Completed | Fimasartan Achieving SBP Target (FAST) Study NCT02495324 | Boryung Pharmaceutical Co., Ltd | Phase 4 |
| Unknown | Treatment of HYpertension: Morning Versus Evening NCT02214498 | Erasmus Medical Center | Phase 4 |
| Completed | Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hyp NCT02738632 | IlDong Pharmaceutical Co Ltd | Phase 3 |
| Completed | The Northwest Coalition for Primary Care Practice Support NCT02839382 | Kaiser Permanente | N/A |
| Completed | RAS Peptide Profiles in Patients With Arterial Hypertension NCT02449811 | Insel Gruppe AG, University Hospital Bern | — |
| Completed | A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects NCT02345044 | Daiichi Sankyo | Phase 2 |
| Completed | Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension NCT02322450 | Quantum Genomics SA | Phase 2 |
| Unknown | Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II NCT02407210 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hype NCT02368652 | HK inno.N Corporation | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hype NCT02368665 | HK inno.N Corporation | Phase 3 |
| Unknown | Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Ce NCT02357615 | Shanghai Shyndec Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension NCT02277691 | Takeda | Phase 3 |
| Terminated | The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hype NCT01938911 | Insel Gruppe AG, University Hospital Bern | N/A |
| Completed | The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension NCT02419235 | University of Johannesburg | Phase 2 |
| Unknown | Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension P NCT02277821 | Stendo | N/A |
| Completed | Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dos NCT02944734 | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 |
| Withdrawn | Microvascular Function in Primary Aldosteronism NCT02096939 | Maastricht University Medical Center | — |
| Completed | To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers NCT02579356 | Samil Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Fimasartan/Amlodipine Combination Phase III NCT02152306 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension NCT02206165 | Chong Kun Dang Pharmaceutical | Phase 2 |
| Completed | Study of Efficacy and Safety of CVAA489 in Hypertensive Patients NCT02062645 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hyperten NCT02031861 | Shanghai Shyndec Pharmaceutical Co., Ltd. | Phase 4 |
| Unknown | A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertensio NCT02059616 | HK inno.N Corporation | Phase 2 |
| Completed | PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension NCT02058446 | TSH Biopharm Corporation Limited | Phase 4 |
| Completed | Helius in Hypertension-I: The UK Hypertension Registry NCT02553512 | Proteus Digital Health, Inc. | — |
| Unknown | Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine NCT01956786 | Shenzhen Ausa Pharmed Co.,Ltd | Phase 2 / Phase 3 |
| Unknown | GRK4 Polymorphisms Blood Pressure Response to Candesartan NCT01629225 | Third Military Medical University | Phase 4 |
| Completed | Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension NCT02412761 | The University of Texas Health Science Center, Houston | N/A |
| Unknown | Study of Personalized Dietary Intervention for the Control of Essential Hypertension NCT02136264 | University of Nigeria, Enugu Campus | N/A |
| Completed | Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerabil NCT01873885 | PhaseBio Pharmaceuticals Inc. | Phase 1 |
| Completed | A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy NCT01878201 | Boryung Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) NCT02385721 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in P NCT01838850 | Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company | Phase 3 |
| Completed | Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension NCT01785472 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine NCT01842230 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tab NCT01819870 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Completed | Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin. NCT01842256 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Unknown | Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function NCT01825759 | West China Hospital | Phase 4 |
| Unknown | Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine NCT01848873 | Shenzhen Ausa Pharmed Co.,Ltd | Phase 2 / Phase 3 |
| Completed | Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects NCT01900184 | Quantum Genomics SA | Phase 1 |
| Completed | Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism NCT02938910 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Pati NCT01663233 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension NCT01615198 | Novartis Pharmaceuticals | Phase 3 |
| Completed | The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension NCT01679652 | Erling Bjerregaard Pedersen | Phase 2 |
| Completed | Effect of Acupuncture on Patients With Mild Hypertension NCT01701726 | Chengdu University of Traditional Chinese Medicine | Phase 3 |
| Completed | Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension NCT01599104 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension NCT01631227 | Abbott | Phase 3 |
| Completed | Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia NCT01541943 | HanAll BioPharma Co., Ltd. | Phase 3 |
| Unknown | Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones NCT01617551 | Regional Hospital Holstebro | N/A |
| Completed | Perindopril Amlodipine for the Treatment of Hypertension NCT01556997 | Symplmed Pharmaceuticals LLC | Phase 3 |
| Completed | Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo NCT01900171 | Quantum Genomics SA | Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following NCT01523067 | PhaseBio Pharmaceuticals Inc. | Phase 1 |
| Completed | A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlor NCT01456169 | Takeda | Phase 3 |
| Unknown | Renal Sympathetic Modification in Patients With Essential Hypertension NCT01417221 | The Second Affiliated Hospital of Chongqing Medical University | N/A |
| Unknown | Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene NCT01320397 | RostaQuo S.p.A. | Phase 2 |
| Completed | Resistant Arterial Hypertension Cohort Study NCT01083017 | University Hospital, Geneva | — |
| Completed | The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. NCT01295021 | AstraZeneca | — |
| Completed | Essential Hypertension NCT01264692 | Idorsia Pharmaceuticals Ltd. | Phase 2 |
| Completed | Vascular Impact of Omega-3 in Metabolic Syndrome NCT01566188 | University Hospital, Rouen | N/A |
| Unknown | Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension NCT01413048 | Ahn-Gook Pharmaceuticals Co.,Ltd | Phase 3 |
| Completed | Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hyperte NCT01237873 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Intensive Vasodilator Therapy in Patients With Essential Hypertension NCT01180413 | Aarhus University Hospital | Phase 4 |
| Completed | A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy NCT01258673 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertens NCT01256411 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hype NCT01237223 | Novartis | Phase 3 |
| Completed | Canrenone as Add-on in Patients With Essential Hypertension NCT02687178 | University of Pavia | Phase 4 |
| Completed | Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and NCT01198249 | Yonsei University | Phase 1 |
| Completed | The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables NCT01195805 | Regional Hospital Holstebro | N/A |
| Completed | A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in H NCT01146938 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure NCT01667614 | Tehran University of Medical Sciences | Phase 2 |
| Completed | Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Block NCT01113047 | Novartis | Phase 3 |
| Terminated | The Confirmatory Olmesartan Plaque Regression Study NCT01132768 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Phase 4 |
| Completed | Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination i NCT01127139 | Abbott | — |
| Completed | Hybrid Blood Pressure Monitor Validation NCT01120990 | University of Athens | Phase 4 |
| Completed | Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension NCT01093807 | RECORDATI GROUP | Phase 2 |
| Completed | Inflammatory Response to Salt in Essential Hypertension NCT01665534 | Carmine Zoccali | Phase 3 |
| Completed | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlor NCT01033071 | Takeda | Phase 3 |
| Unknown | Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension NCT00994617 | University of Cambridge | Phase 4 |
| Completed | Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension NCT01122251 | LG Life Sciences | Phase 2 |
| Completed | Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypert NCT01131546 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 4 |
| Completed | Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients NCT01042392 | Novartis | Phase 4 |
| Completed | Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydr NCT00996281 | Takeda | Phase 3 |
| Completed | Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension NCT01001572 | Novartis | Phase 3 |
| Completed | A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Vo NCT00991783 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteer NCT00991705 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety o NCT00938132 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension NCT00923091 | Daiichi Sankyo | Phase 3 |
| Completed | A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan an NCT00938197 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension NCT00902538 | Daiichi Sankyo | Phase 3 |
| Completed | A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy NCT00938262 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypert NCT00846365 | Takeda | Phase 3 |
| Completed | A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hyd NCT00923533 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hyperte NCT00818883 | Takeda | Phase 3 |
| Unknown | Home Blood Pressure in Hypertension Management NCT00841308 | University of Athens | Phase 4 |
| Completed | Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasa NCT00937534 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) NCT00922441 | Boryung Pharmaceutical Co., Ltd | Phase 2 |
| Completed | In-practice Evaluation of Atacand 16mg Antihypertensive Effect NCT00802542 | AstraZeneca | — |
| Completed | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma NCT01022515 | University Hospital, Rouen | N/A |
| Completed | A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension NCT00758524 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment NCT00741585 | University of Vigo | Phase 4 |
| Unknown | Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients NCT00716950 | University of Pavia | Phase 4 |
| Completed | A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participant NCT00667719 | Novartis | Phase 3 |
| Unknown | Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular NCT00659451 | University of Pavia | Phase 3 |
| Unknown | Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertensi NCT00644475 | University of Pavia | Phase 3 |
| Completed | Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliski NCT00654875 | Novartis | Phase 4 |
| Completed | Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hype NCT00709930 | Kyoto University | Phase 2 |
| Completed | Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension NCT00461903 | Montreal Heart Institute | Phase 3 |
| Completed | Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets NCT00553865 | Jeil Pharmaceutical Co., Ltd. | Phase 2 |
| Unknown | Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients NCT01011660 | Chinese Academy of Medical Sciences, Fuwai Hospital | Phase 4 |
| Completed | Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on NCT00509470 | Tokyo University | Phase 4 |
| Completed | Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension NCT01289132 | Takeda | Phase 2 |
| Completed | Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions NCT01013155 | Roxane Laboratories | N/A |
| Completed | Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions NCT01012687 | Roxane Laboratories | N/A |
| Completed | Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension NCT00430950 | Daiichi Sankyo | Phase 3 |
| Completed | Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension NCT00430508 | Daiichi Sankyo | Phase 3 |
| Completed | The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension NCT00438945 | Regional Hospital Holstebro | Phase 4 |
| Completed | Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH NCT00607633 | AstraZeneca | — |
| Completed | Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide NCT00608153 | AstraZeneca | — |
| Completed | Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension NCT00138944 | University of Erlangen-Nürnberg Medical School | Phase 3 |
| Completed | Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension NCT00437645 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study NCT00408512 | Federico II University | Phase 4 |
| Completed | Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension NCT00425373 | Novartis Pharmaceuticals | Phase 2 / Phase 3 |
| Unknown | Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension NCT00380289 | University of Cambridge | N/A |
| Completed | Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in NCT00872586 | Daiichi Sankyo | Phase 3 |
| Completed | Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension NCT00890591 | Daiichi Sankyo | Phase 4 |
| Unknown | Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension NCT00366119 | Pacific Pharmaceuticals | Phase 4 |
| Completed | Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Mis NCT00343551 | Novartis | Phase 3 |
| Completed | The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension NCT01342614 | China-Japan Friendship Hospital | N/A |
| Terminated | Loaded Breathing Training in Essential Hypertension NCT00791986 | Khon Kaen University | N/A |
| Completed | L-Arginine Metabolism in Essential Hypertension NCT00137124 | University of Erlangen-Nürnberg Medical School | Phase 2 / Phase 3 |
| Completed | Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension NCT00311155 | Sankyo Pharma Gmbh | Phase 4 |
| Completed | A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hyperte NCT00254475 | Novartis | Phase 3 |
| Completed | Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypert NCT00139698 | Pfizer | Phase 3 |
| Completed | Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) NCT00937651 | Boryung Pharmaceutical Co., Ltd | Phase 2 |
| Completed | Amlodipine as add-on to Olmesartan in Hypertension NCT00220220 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Olmesartan as an add-on to Amlodipine in Hypertension NCT00220233 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314) NCT00157963 | Organon and Co | Phase 4 |
| Completed | Efficacy of Rostafuroxin in the Treatment of Essential Hypertension NCT00415038 | sigma-tau i.f.r. S.p.A. | Phase 2 |
| Completed | Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea NCT00328965 | GlaxoSmithKline | Phase 4 |
| Completed | Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension V NCT00500786 | Cytos Biotechnology AG | Phase 1 / Phase 2 |
| Completed | Uric Acid in Essential Hypertension in Children NCT00288184 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension NCT00856271 | Daiichi Sankyo | Phase 3 |
| Completed | Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease NCT00298129 | Yokohama City University Medical Center | — |
| Completed | Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects NCT01289899 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy NCT00295555 | Yokohama City University Medical Center | Phase 4 |
| Completed | Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects NCT01289886 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Olmesartan Medoxomil in Hypertension and Renal Impairment NCT00151827 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly NCT00751751 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Phase 3 |
| Terminated | Motivational Interviewing NCT00208104 | Columbia University | N/A |
| Completed | Olmesartan Medoxomil Versus Losartan in Patients With Hypertension NCT00857285 | Daiichi Sankyo | Phase 3 |
| Completed | Olmesartan in Essential Hypertension NCT00185172 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Olmesartan Medoxomil in Atherosclerosis NCT00185185 | Sankyo Pharma Gmbh | Phase 3 |
| Completed | Hypertension: Prediction of Biofeedback Success NCT00026065 | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 |
| Completed | Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension NCT06395194 | Oslo University Hospital | Phase 3 |
| Completed | Heart Rate Variability in White Coat Hypertension and Essential Hypertension NCT00286884 | Regional Hospital Holstebro | — |